|
May 14
|
Wall Street Analysts Think ALX Oncology Holdings (ALXO) Could Surge 36.64%: Read This Before Placing a Bet
|
|
May 10
|
ALX Oncology Holdings Inc (ALXO) Q1 2024 Earnings Analysis: A Detailed Look at Financials and ...
|
|
May 9
|
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 7
|
ALX Oncology Appoints Allison Dillon as Chief Business Officer
|
|
Apr 30
|
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
|
|
Apr 24
|
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
|
|
Apr 15
|
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
|
|
Apr 11
|
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
|
|
Apr 9
|
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
|
|
Apr 6
|
ALX Oncology Holdings Inc (ALXO) Insider Sells Shares
|
|
Mar 8
|
ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer
|
|
Mar 8
|
ALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D Spending
|
|
Mar 7
|
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
|
Mar 5
|
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
|
|
Nov 13
|
ALX Oncology Holdings Inc (ALXO) Reports Q3 2023 Financial Results and Corporate Developments
|
|
Nov 13
|
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
|
|
Nov 1
|
ALX Oncology Announces November Investor Conference Participation
|
|
Aug 31
|
ALX Oncology Announces September Investor Conference Participation
|
|
Apr 25
|
ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma
|